EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., December 4, 2023 (GLOBE NEWSWIRE) EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and

commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering of $175 million of shares of its common stock. All of the shares are being

offered by EyePoint. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $26.25 million of shares of EyePoint s common stock at the public offering price, less the

underwriting discount.

J.P. Morgan, TD Cowen and Guggenheim Securities are acting as joint book running managers for the offering. The offering is

subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of

EYP-1901 for wet age related macular degeneration through the initiation of and reporting of topline data from two pivotal Phase 3 clinical trials, as well as support its earlier stage pipeline development

initiatives, and for general corporate purposes.

The securities described above to be issued and sold are being offered by the Company pursuant to a

shelf registration statement on Form S-3 (No. 333-275125) previously filed with the Securities and Exchange Commission (SEC) on October 20, 2023 and declared

effective by the SEC on October 30, 2023.

The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to

the offering that form a part of the applicable registration statements. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the

SEC s website at www.sec.gov. Copies of the preliminary prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long

Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at

Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at

(212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall

not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful

prior to registration or qualification under the securities laws of any such state or jurisdiction.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage company committed to developing and commercializing therapeutics to help improve the lives of

patients with serious retinal diseases. The Company s pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. The company s

lead product candidate, EYP-1901, is an investigational sustained delivery

treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with Durasert

E . Vorolanib is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases. Additional pipeline programs include EYP-2301, a promising Tie-2 activator, razuprotafib, f/k/a AKB-9778, formulated in Durasert E to potentially improve outcomes in wet AMD and diabetic eye disease. The proven Durasert drug delivery platform has been safely

administered to over thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that

is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the timing and success of the proposed offering, as well as the

anticipated use of proceeds for the proposed offering and other statements identified by words such as will, potential, could, can, believe, intends, continue,

plans, expects, anticipates, estimates, may, other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different

degrees, uncertain. Uncertainties and risks may cause EyePoint s actual results to be materially different than those expressed in or implied by EyePoint s forward-looking statements. For EyePoint, this includes satisfaction of the

customary closing conditions of the offering, delays in obtaining required stock exchange or other regulatory approvals, stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy, and

the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market. More detailed information on these and additional factors that could affect EyePoint s actual results

are described in EyePoint s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as revised or supplemented by its Quarterly Reports on

Form 10-Q and other documents filed with the SEC. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint undertakes no obligation to update or revise any

forward-looking statement, whether as a result of new information, future events or otherwise.

Direct: 212-698-8700

Green Room Communications

Direct: 412-327-9499